Shubham Pant, MD, MBBS, explains the significance of the FDA approval of daraxonrasib for mPDAC.
Shubham Pant, MD, MBBS
Advertisement
Shubham Pant, MD, is a professor in the Department of Gastrointestinal (GI) Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics (Phase I Center) at the UT MD Anderson Cancer Center.
Articles by Shubham Pant, MD, MBBS
Dr Pant highlights phase 3 data showing oral daraxonrasib nearly doubles overall survival vs chemotherapy in metastatic pancreatic cancer.
Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.
Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.
Shubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Rezatapopt Shows 46% ORR in TP53 Y220C–Mutated Ovarian Cancer
2
First-Line Savolitinib/Osimertinib Improves PFS in MET+ NSCLC
3
G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC
4
Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer
5